Versant Vantage I Gp-Gp, LLC
CIK 0001777653 Name as filed on the most recent filing
Filed as Versant Vantage I Gp-Gp, LLC (12)
32 transaction lines · from 12 filings · filed 2019-10-07 to 2025-09-23 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Lava Therapeutics NV 2 filings
- ISSUER Monte Rosa Therapeutics, Inc. 4 filings
- ISSUER Repare Therapeutics Inc. 2 filings
- ISSUER Oyster Point Pharma, Inc. 2 filings
- ISSUER Passage BIO, Inc. 1 filings
- ISSUER Aprea Therapeutics, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-09-19 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 2,370,533 disposed | 1.40 | 3,322,064.95 | Form 4, filing 0001193125-25-213445 | |
| 2025-09-19 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 532,870 disposed | 1.40 | 746,764.02 | Form 4, filing 0001193125-25-213445 | |
| 2025-09-18 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 366,111 disposed | 1.44 | 527,858.84 | Form 4, filing 0001193125-25-207677 | |
| 2025-09-18 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 228,791 disposed | 1.44 | 329,870.86 | Form 4, filing 0001193125-25-207677 | |
| 2025-09-17 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 362,806 disposed | 1.49 | 540,290.70 | Form 4, filing 0001193125-25-207677 | |
| 2025-09-17 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 226,726 disposed | 1.49 | 337,640.36 | Form 4, filing 0001193125-25-207677 | |
| 2025-09-16 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 307,707 disposed | 1.53 | 471,776.37 | Form 4, filing 0001193125-25-207677 | |
| 2025-09-16 |
Lava Therapeutics NV LVTX |
S, Open-market sale | 192,293 disposed | 1.53 | 294,823.63 | Form 4, filing 0001193125-25-207677 | |
| 2024-10-29 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 52,305 disposed | 9.08 | 475,007.86 | Form 4, filing 0000950170-24-119051 | |
| 2024-10-29 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 15,600 disposed | 9.41 | 146,792.88 | Form 4, filing 0000950170-24-119051 | |
| 2024-10-28 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 89,990 disposed | 9.66 | 869,240.41 | Form 4, filing 0000950170-24-119051 | |
| 2024-09-20 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 1,132,566 disposed | 6.53 | 7,395,202.95 | Form 4, filing 0000950170-24-109112 | |
| 2024-09-13 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 9,269 disposed | 6.16 | 57,099.82 | Form 4, filing 0000950170-24-106532 | |
| 2024-09-12 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 16,047 disposed | 6.00 | 96,309.28 | Form 4, filing 0000950170-24-106532 | |
| 2024-09-11 |
Monte Rosa Therapeutics, Inc. GLUE |
S, Open-market sale | 541,897 disposed | 6.00 | 3,251,382.00 | Form 4, filing 0000950170-24-106532 | |
| 2022-06-03 |
Repare Therapeutics Inc. RPTX |
S, Open-market sale | 438,795 disposed | 12.25 | 5,375,984.70 | Form 4, filing 0000899243-22-021350 | |
| 2022-06-03 |
Repare Therapeutics Inc. RPTX |
S, Open-market sale | 250,000 disposed | 12.25 | 3,062,925.00 | Form 4, filing 0000899243-22-021350 | |
| 2022-06-03 |
Repare Therapeutics Inc. RPTX |
S, Open-market sale | 33,395 disposed | 12.25 | 409,145.52 | Form 4, filing 0000899243-22-021350 | |
| 2022-06-03 |
Repare Therapeutics Inc. RPTX |
S, Open-market sale | 14,611 disposed | 12.25 | 179,009.59 | Form 4, filing 0000899243-22-021350 | |
| 2022-06-03 |
Repare Therapeutics Inc. RPTX |
S, Open-market sale | 13,199 disposed | 12.25 | 161,710.19 | Form 4, filing 0000899243-22-021350 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 303,614 disposed | 14.63 | 4,442,692.58 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 242,943 disposed | 15.09 | 3,666,957.35 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 1,912 disposed | 14.63 | 27,977.72 | Form 4, filing 0000899243-21-040777 | |
| 2021-10-18 |
Oyster Point Pharma, Inc. OYST |
S, Open-market sale | 1,531 disposed | 15.09 | 23,108.76 | Form 4, filing 0000899243-21-040777 | |
| 2021-06-28 |
Monte Rosa Therapeutics, Inc. GLUE |
P, Open-market purchase | 157,895 acquired | 19.00 | 3,000,005.00 | Form 4, filing 0000899243-21-026766 | |
| 2020-06-23 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 150,000 acquired | 20.00 | 3,000,000.00 | Form 4, filing 0001209191-20-039019 | |
| 2020-06-23 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 100,000 acquired | 20.00 | 2,000,000.00 | Form 4, filing 0001209191-20-039019 | |
| 2020-03-03 |
Passage BIO, Inc. PASG |
P, Open-market purchase | 225,000 acquired | 18.00 | 4,050,000.00 | Form 4, filing 0001209191-20-015670 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 437,500 acquired | 16.00 | 7,000,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 125,000 acquired | 16.00 | 2,000,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2019-11-04 |
Oyster Point Pharma, Inc. OYST |
P, Open-market purchase | 27,500 acquired | 16.00 | 440,000.00 | Form 4, filing 0000899243-19-026602 | |
| 2019-10-07 |
Aprea Therapeutics, Inc. APRE |
P, Open-market purchase | 333,333 acquired | 15.00 | 4,999,995.00 | Form 4, filing 0001140361-19-018091 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Versant Vantage I GP-GP, LLC, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001777653
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6